Par value $0.

Amgen programs $5 billion auction tender offer Amgen today announced its plan to start a modified Dutch auction tender offer to get up to $5 billion of its common share, par value $0 .0001 per share . ‘This tender present reflects Amgen’s confidence in the future outlook of our business and the Company’s long-term value,’ said Kevin W. Sharer, CEO and Chairman at Amgen.’ Altered Dutch Auction Tender Offer Amgen will offer to get up to $5 billion of Common Share at a price not higher than $60.00 nor significantly less than $54.00 per share.

Amgen announces Phase 3 outcomes evaluating Vectibix in combination with FOLFIRI chemotherapy Amgen today announced detailed results from the Phase 3 ‘181’ trial evaluating Vectibix) in combination with FOLFIRI , while a second-range treatment for metastatic colorectal cancer . In this trial, Vectibix significantly improved progression-free of charge survival in sufferers with KRAS wild-type mCRC. These results were presented at the 2009 2009 ECCO 15 – 34 European Multidisciplinary Congress in Berlin ESMO, Germany . The addition of Vectibix to FOLFIRI significantly improved median PFS by 8 weeks therapy such as for example rash, diarrhea, and hypomagnesemia.